Opioid switch from low dose of oral oxycodone to transdermal fentanyl matrix patch for patients with stable thoracic malignancy-related pain.

ABSTRACT:

Background

The effectiveness and safety of switch from oral oxycodone to fentanyl patch is little known. Here, we investigated if early phase opioid switch from low dose of oral oxycodone to transdermal fentanyl matrix patch provided any benefits for patients with thoracic malignancy and stable cancer-related pain.

Methods

This open-label two-centered prospective study enrolled patients with thoracic malignancy suffering persistent malignancy-related pain with numeric rating scale of pain intensity???3 which had been controlled by oral oxycodone???20 mg/day. Eligible patients switched from oral oxycodone to 12.5 ?g/h of transdermal fentanyl matrix patch. The dose was allowed to be titrated upwards every 3 day by 25-50%, except for the first increase from 12.5 ?g/hr to 25 ?g/hr,until achieving adequate pain control. The data on patients' global assessment scores measured on a five-step scale, an 11-point numeric rating scale of pain intensity, the severity of adverse effects using a four-point categorical rating scale, and the Epworth sleepiness scale questionnaire were collected for 15 days.

Results

Forty-nine eligible patients were analyzed. Overall patients' satisfaction score significantly improved from day 1 (2.7?±?0.9) to day 15 (2.3?±?0.9) (p?ConclusionTransdermal fentanyl matrix patch is an alternative analgesic option for a stable cancer pain in patients with thoracic malignancies.

SUBMITTER: Minami S 

PROVIDER: S-EPMC4195703 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature